SCHEDULE 13D
This Amendment No. 5 (“Amendment No. 5”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission on July 27, 2023 (the “Initial Schedule 13D” and together with Amendment No. 1 thereto filed on August 7, 2023, Amendment No. 2 thereto filed on August 28, 2023, Amendment No. 3 thereto filed on January 3, 2024, Amendment No. 4 filed on July 15, 2024 and this Amendment No. 5, the “Schedule 13D”) by Todd Deutsch and Ted D. Kellner (the “Reporting Persons”) with respect to the Common Stock, par value $0.001 per share, of AIM ImmunoTech Inc. (the “Company”). Capitalized terms used herein and not otherwise defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D. This Amendment No. 5 amends Items 4 and 6 to the extent set forth below.
Item 4. Purpose of the Transaction
Item 4 is hereby supplemented as follows:
On July 26, 2024, Mr. Kellner filed a motion for reargument with the Delaware Supreme Court. Mr. Kellner requested that the court declare he is entitled to relief from the inequitable conduct of the AIM board of directors and that the action be remanded for further proceedings requiring AIM to accept Mr. Kellner’s nominations at the next annual or special meeting. The motion also asked for clarification that the trial court retains jurisdiction for any fee applications. Mr. Kellner’s motion was denied on July 29, 2024.
The Reporting Persons continue to review alternatives that may be available to them as described in Amendment No. 4. In connection with this review, the Reporting Persons note that the Company has announced that it plans to amend its bylaws to comport with the ruling of the Delaware Supreme Court. The Reporting Persons will consider the Company’s amended bylaws once available.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
Item 6 is hereby supplemented as follows:
The Group Agreement entered into by the Reporting Persons and Mr. Chioini on July 26, 2023, as amended on January 3, 2024, automatically expired in accordance with its terms on July 26, 2024. Notwithstanding the expiration of the Group Agreement, the Reporting Persons, together with Mr. Chioini, continue to coordinate with respect to the actions described in Item 4 above. As such, the Reporting Persons would likely be deemed to remain a “group” within the meaning of Section 13(d) of the Exchange Act. The Reporting Persons, together with Mr. Chioini, expect to consider whether to renew or replace the Group Agreement as part of their ongoing review.